A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs NN 9030 (Primary) ; Liraglutide
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
- 23 Aug 2016 Status changed from recruiting to completed.
- 11 Dec 2015 Planned number of patients changed from 160 to 176, according to ClinicalTrials.gov record.
- 22 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016, according to ClinicalTrials.gov record.